eEF2K—a new target in breast cancers with combined inactivation of p53 and PTEN
Abstract Extensive efforts have now characterized the somatic molecular alterations in human breast cancer (Cancer Genome Atlas Network, 2012; Stephens et al, 2012) and have led to a re‐definition of the disease as a constellation of 10 distinct driver‐based subtypes (IntClust subtypes) (Curtis et a...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2014-12-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.201404683 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849343404948848640 |
|---|---|
| author | Hege G Russnes Carlos Caldas |
| author_facet | Hege G Russnes Carlos Caldas |
| author_sort | Hege G Russnes |
| collection | DOAJ |
| description | Abstract Extensive efforts have now characterized the somatic molecular alterations in human breast cancer (Cancer Genome Atlas Network, 2012; Stephens et al, 2012) and have led to a re‐definition of the disease as a constellation of 10 distinct driver‐based subtypes (IntClust subtypes) (Curtis et al, 2012). The pursuit of druggable targets for each of these subtypes is now pressing. This is elegantly illustrated by the work of Liu et al (2014). |
| format | Article |
| id | doaj-art-66a7a1f98438416da8cd9951d9d83c4f |
| institution | Kabale University |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2014-12-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-66a7a1f98438416da8cd9951d9d83c4f2025-08-20T03:43:01ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842014-12-016121512151410.15252/emmm.201404683eEF2K—a new target in breast cancers with combined inactivation of p53 and PTENHege G Russnes0Carlos Caldas1Department of Genetics, Institute for Cancer Research and Department of Pathology, Oslo University HospitalCancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of CambridgeAbstract Extensive efforts have now characterized the somatic molecular alterations in human breast cancer (Cancer Genome Atlas Network, 2012; Stephens et al, 2012) and have led to a re‐definition of the disease as a constellation of 10 distinct driver‐based subtypes (IntClust subtypes) (Curtis et al, 2012). The pursuit of druggable targets for each of these subtypes is now pressing. This is elegantly illustrated by the work of Liu et al (2014).https://doi.org/10.15252/emmm.201404683 |
| spellingShingle | Hege G Russnes Carlos Caldas eEF2K—a new target in breast cancers with combined inactivation of p53 and PTEN EMBO Molecular Medicine |
| title | eEF2K—a new target in breast cancers with combined inactivation of p53 and PTEN |
| title_full | eEF2K—a new target in breast cancers with combined inactivation of p53 and PTEN |
| title_fullStr | eEF2K—a new target in breast cancers with combined inactivation of p53 and PTEN |
| title_full_unstemmed | eEF2K—a new target in breast cancers with combined inactivation of p53 and PTEN |
| title_short | eEF2K—a new target in breast cancers with combined inactivation of p53 and PTEN |
| title_sort | eef2k a new target in breast cancers with combined inactivation of p53 and pten |
| url | https://doi.org/10.15252/emmm.201404683 |
| work_keys_str_mv | AT hegegrussnes eef2kanewtargetinbreastcancerswithcombinedinactivationofp53andpten AT carloscaldas eef2kanewtargetinbreastcancerswithcombinedinactivationofp53andpten |